No Data
No Data
Chemomab Therapeutics Aligns Leadership Incentives With Shareholders
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Express News | Chemomab Therapeutics Ltd. : Oppenheimer Cuts Target Price to $11 From $13
Chemomab Therapeutics Sees Cash Runway Through Beginning of 2026